Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.40 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | BAP1 | Q92560 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050136 | 0.86 | ALDH1A1 (0.51) | POLBSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL3050166 | 0.84 | SCD (0.48) | SMN1; SMN2LMNAMEN1KMT2ATP53 | |
| SCHEMBL10728962 | 0.69 | NPC1 (0.67) | POLBNPC1RAB9ALMNAHPGD | |
| SCHEMBL3585269 | 0.68 | KDM4E (0.56) | SMN1; SMN2NPC1RAB9ALMNAMEN1 | |
| SCHEMBL20556982 | 0.68 | MMP9 (0.50) | POLBSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL166807 | 0.67 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 | |
| SCHEMBL25064112 | 0.67 | NPC1 (0.59) | NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL16267379 | 0.66 | NPC1 (0.58) | POLBNPC1RAB9ALMNAHPGD | |
| SCHEMBL2210517 | 0.65 | NPC1 (0.77) | NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL8983945 | 0.65 | NPC1 (0.49) | POLBSMN1; SMN2NPC1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101595105-A | 5 membered heterocyclic compounds that replace as the 2-of SCD inhibitor | NOVARTIS AG XENON PHARMACEUTIC (CH) | 2009-12-02 | — | — | CN | claimed |
| EP-2121671-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | claimed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | claimed |
| CN-101595105-B | 2-substituted 5-membered heterocycles as SCD inhibitors | NOVARTIS AG | 2013-01-23 | — | — | CN | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| CN-101595105-A | 5 membered heterocyclic compounds that replace as the 2-of SCD inhibitor | NOVARTIS AG XENON PHARMACEUTIC (CH) | 2009-12-02 | — | — | CN | disclosed |
| EP-2121671-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029722-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | POLB 2337/4885SMN1; SMN2 3581/4885NPC1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.